Why Roche is 'really excited' about a UCN2 analog for obesity after seeing preclinical data

Roche has decided to pay $190 million upfront for an unusual obesity mechanism after viewing preclinical data that “clearly suggests” the modality can reduce weight while preserving lean muscle, Fierce has learned.